M.R. Prow

[3H]Nisoxetine—A radioligand for noradrenaline reuptake sites: Correlation with inhibition of [3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments

Sharon C. Cheetham, Jean Viggers, Sarah Butler et al. · Neuropharmacology · 1996 · 123 citations

Medicine, Neuroscience, Pharmacology +17

A comparison of the effects on central 5‐HT function of sibutramine hydrochloride and other weight‐modifying agents

D.J. Heal, Sharon C. Cheetham, M.R. Prow et al. · British Journal of Pharmacology · 1998 · 105 citations · Full text

Medicine, Neuroscience, Pharmacology +15

A comparison of the effects of sibutramine hydrochloride, bupropion and methamphetamine on dopaminergic function: evidence that dopamine is not a pharmacological target for sibutramine

David J. Heal, A. T. J. Frankland, Jane Gosden et al. · Psychopharmacology · 1992 · 63 citations

Medicine, Neuroscience, Pharmacology +16

Comparison of the effects of sibutramine and other weight-modifying drugs on extracellular dopamine in the nucleus accumbens of freely moving rats

Helen L. Rowley, Sarah Butler, M.R. Prow et al. · Synapse · 2000 · 40 citations

Life Sciences, Neuroscience, Pharmacology +17

Measurement of 3‐methoxy‐4‐hydroxyphenylglycol (MHPG) in mouse brain by h.p.l.c. with electrochemical detection, as an index of noradrenaline utilisation and presynaptic α₂‐adrenoceptor function

David J. Heal, M.R. Prow, W. R. Buckett · British Journal of Pharmacology · 1989 · 36 citations · Full text

Medicine, Neuroscience, Pharmacology +16